ALBAUGH, LLC v. BASF SE

ALBAUGH, LLC v. BASF SE (PGR2026-00026) involves a challenge to the patentability of a recently issued agricultural chemical patent owned by BASF SE. ALBAUGH, LLC, the petitioner, is a privately held, global leader in the production and sale of post-patent (generic) crop protection products, including herbicides, fungicides, and insecticides, serving farmers worldwide. BASF SE, the patent owner, is a German multinational chemical company and the world's largest chemical producer, with a substantial "Agricultural Solutions" segment that develops and sells innovative crop protection products, seeds, and traits globally. This dispute highlights the competitive dynamics within the agricultural chemicals industry, where generic manufacturers often seek to challenge and enter markets traditionally dominated by proprietary products from major innovators.

The patent at issue is U.S. Patent No. 12,305,206, which generally relates to plant growth regulators. Plant growth regulators are compounds that significantly influence various aspects of plant development, such as root, shoot, and embryo growth, and are used to modify and regulate plant growth, affecting aspects like fruit ripening, plant height, and seed development. The specific technical details challenged by ALBAUGH, LLC will be elaborated in their petition, but the patent broadly covers methods or compositions for modulating plant growth.

This case is currently in the pre-institution phase before the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO). This venue is critical because Post-Grant Review (PGR) provides a specialized, administrative forum for challenging the validity of a U.S. patent shortly after its issuance, offering a potentially faster and more cost-effective alternative to district court litigation for resolving patent validity issues. Unlike Inter Partes Review (IPR), PGR allows for a broader range of invalidity grounds, including lack of novelty, obviousness, and written description, and can consider prior public use or sale, not just patents and printed publications. The case is notable as it represents a generic competitor's proactive move to clear the path for market entry by challenging a new patent from an industry incumbent, leveraging the PTAB's mechanisms to address patentability early in a patent's life cycle.

I'll research the current status of this proceeding and any parallel litigation. Note at the outset: this is a PTAB post-grant review, not a district court infringement action, so the "litigation" milestones map onto PTAB-specific events (petition, POPR, institution decision, scheduling order, PO response, sur-reply, oral hearing, final written decision) rather than pleadings/Markman/trial. Let me verify what has actually happened.

Key finding already: third-party trackers show the case as instituted with an institution decision dated 2026-07-28, and identify BASF's counsel as Matias Ferrario. Let me verify both against primary sources and look for parallel district court litigation.

Let me dig into the docket after institution and search for parallel proceedings and litigation.

Threshold note on framing

This docket is not a patent infringement litigation. PGR2026-00026 is an administrative validity trial at the PTAB. There is therefore no complaint, answer, counterclaim, Rule 12 motion, transfer motion, Markman hearing, jury trial, JMOL/new-trial motion, or damages verdict. The equivalent milestones are: petition → notice of accord → patent owner mandatory notices → POPR → institution decision → scheduling order → patent owner response → petitioner reply → sur-reply → oral hearing → final written decision → Request for Director Review / Federal Circuit appeal.

Two corrections to the earlier sections, with sourcing caveats:

1. Patent subject matter. The existing overview describes the '206 patent as "generally relat[ing] to plant growth regulators." Third-party petition analyses describe U.S. 12,305,206 as "Methods for Making L-Glufosinate" and characterize the claims as aqueous herbicidal formulations of L-glufosinate ammonium at >90% enantiomeric purity plus selected surfactants/solvents (sodium alkyl ether sulfate, 1-methoxy-2-propanol, dipropylene glycol, alkyl polysaccharide), with water as balance. Glufosinate is a herbicide, not a plant growth regulator — so the overview's characterization appears to be an error. (petition analysis)
2. Petitioner's Power of Attorney date. The earlier section states a POA filed 2026-02-10. The docket index shows the Petitioner's Power of Attorney filed 2026-02-20, the same day as the petition. The 02-10 date is unsupported by anything I could retrieve.

---

Chronological developments

Grounds actually at issue (per petition analyses)

• Ground 1 — § 102 anticipation of claim 1 by Long (U.S. 8,445,406), with enablement of the >90% L‑enantiomer supplied by the "L-Glufosinate Synthesis References" (Schulz, Zeiss, Grabley, Nakanishi, Minowa, Knorr). Albaugh argues the examiner withdrew an anticipation rejection based on a misreading of Long as raceimate-only; Long allegedly discloses "all stereoisomers," names the L‑enantiomer as "the biologically active isomer," and teaches all four classes of the claimed additional components with overlapping ranges.
• Ground 2 — § 103 over Long alone (claims 1–6), attacking the weight-percentage limitations as routine optimization (e.g., 22% racemic → 11% active L‑isomer; 11% ÷ 0.90 ≈ 12.2%, reaching the claimed 12.25%).
• Ground 3 — § 103 over Long in view of the synthesis references, with motivation supplied by Long's own identification of the L‑enantiomer as the active isomer (efficacy plus reduced environmental load of the D‑isomer).

Posture as of 2026-10-18

The case is instituted and in the trial phase — no final written decision, no appeal, no settlement. Under 35 U.S.C. § 326(a)(11) the Board's final written decision is due within 12 months of institution (i.e., on or about 2027-07-28), extendable by up to six months for good cause. A default PTAB scheduling order would place Patent Owner's Response at roughly three months post-institution — that deadline likely falls at or near today's date, but I could not retrieve the Scheduling Order, the POPR, or any post-institution papers, so I cannot confirm whether BASF filed a preliminary response, whether it has filed its response, whether any motion to amend is contemplated, or whether the Board instituted on all grounds and all claims.

Parallel proceedings

• District court infringement litigation: none identified. Searches surfaced no complaint by BASF against Albaugh on the '206 patent or its L‑glufosinate family in any district court. The only BASF/Albaugh court record located was an unrelated 2008 TTAB trademark opposition (Opp. No. 91180852, PYRAMID), and a trade-press commentary on glufosinate market dynamics. If a parallel district court case exists, it is not well sourced — treat as unverified.
• Other PTAB proceedings: none identified against the '206 patent. Note that the petition's own exhibits (Exs. 1017, 1019, 1021, 1023, 1025 — U.S. 9,834,802; 10,260,078; 10,781,465; 11,560,577; 11,905,538) show this patent sits atop a large BASF L‑glufosinate portfolio, so follow-on challenges to sibling patents are plausible but not confirmed.
• Practical effect on litigation: because no district court case is pending, there is no § 315 stay dynamic to report. The strategic effect of institution runs the other way — BASF now carries the burden of defending claims 1–6 in a forum where Albaugh can leverage the full § 282-type grounds available in PGR (including the priority/derivation and public-use angles hinted at by Ex. 1012).

What to watch next

1. Whether BASF filed a POPR and, if so, whether it argued § 325(d) (the examiner already considered Long — Albaugh's petition squarely attacks the withdrawal of that rejection, which is exactly the kind of "material error" argument that survives § 325(d)).
2. The Scheduling Order's Due Dates and any stipulation extending them.
3. Any contingent motion to amend (BASF would need to revise the weight-percentage claims to escape the routine-optimization theory).
4. Director Review practice under the current regime — even a favorable final written decision may be subject to sua sponte review.

Sourcing caveats

Docket-entry detail (Paper numbers 1–5, exhibit list, institution date of 2026-07-28) is drawn from third-party PTAB aggregators (docket index, IPVerse, Docker Alarm) rather than from PTAB's own PTAB Center/E2E system, which I could not access. The institution decision text (grounds instituted, claims instituted, any partial denial) was not retrievable — the aggregator notes "Decision pending." Also note a conflict in the sources: one aggregator still lists the case status as "Pending" while IPVerse and its competitive-analysis page (last updated 2026-09-18) list "Trial Instituted" with an institution date of 2026-07-28. I have credited the institution reporting as the more specific and more recent signal, but it should be verified against the PTAB's own docket before reliance. BASF's counsel identification (Matias Ferrario et al.) comes from IPVerse and the firm affiliation was not independently confirmed.

I'll search for counsel of record for the petitioner, ALBAUGH, LLC, in PGR2026-00026.

Key lead found: petitioner counsel is Vincent Capuano. Let me identify his firm and any co-counsel.

Counsel of Record — Petitioner ALBAUGH, LLC (PGR2026-00026)

Bottom line: One petitioner-side attorney is publicly identified in the docket-derived data for PGR2026-00026: Vincent L. Capuano, Ph.D. (identified simply as "Petitioner Counsel"). No backup counsel, local counsel, or in-house Albaugh attorney is publicly identified in the sources I could reach, and I could not open the actual Paper 1 Power of Attorney to confirm lead-vs.-backup designation. Treat the firm/office attribution below as high-confidence but not docket-verified for this specific filing.

Sourcing and what it does (and doesn't) establish

• Counsel identification: IP Verse (GreyB) case page for Albaugh, LLC v. BASF SE et al., PGR2026-00026 (filed Feb. 20, 2026), lists under "Counsels Involved": Petitioner Counsel — Capuano, Vincent; Respondent Counsel — Ferrario, Matias et al. — https://ipverse.greyb.com/ptab-web/cases/case-details/PGR2026-00026. This appears to be derived from the Petitioner Power of Attorney filed 2026-02-20 (Paper 1), which the docket aggregator at gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/PGR2026-00026/Albaugh_LLC_v._BASF_SE/ lists on the filing date alongside the Petition (Paper 2) and Exhibits 1001–1027+.
• Who Capuano is / firm: Duane Morris firm biography and press release (LMG Life Sciences Stars, Oct. 7, 2019) — https://dnmrs.com/pressreleases/duane_morris_attorneys_named_lmg_life_sciences_stars_1019.html; career history and representative matters reproduced at https://usattorneys.com/lawyer/vincent-l-capuano-ph-d/ and https://lawtally.com/lawyers/vincent-l-capuano/. Current-firm listing as Capuano IP PLLC (founded 2020, Salem, MA) per Ex Parte attorney profile — https://ai-lab-cl-prod.azurewebsites.net/attorney/[214487](/patent/214487)/vincent-l-capuano — and the firm's 2022 launch notice (CapuanoIP.com, Salem, MA).
• Corroborating signal on the firm/PTAB practice: A PTAB Power of Attorney in IPR2014-01043 lists "Vincent L. Capuano, VCapuano@duanemorris.com, Duane Morris LLP, 100 High Street, Suite 2400, Boston, MA 02110" — confirming his long-standing PTAB practice, but that is a 2014 filing and does not establish his firm in 2026.

Explicit caveats (please read before publishing)

1. Not verified against PTACTS. The authoritative source is the Paper 1 Power of Attorney and the Petition's mandatory notices (37 C.F.R. § 42.8(b)(3)) in PTACTS (ptacts.uspto.gov, proceeding PGR2026-00026). I could not retrieve that document; the identification above rests on third-party docket aggregators that mirror PTACTS. Lead vs. backup counsel ordering, registration numbers, service email, and any additional named attorneys should be pulled from Paper 1 directly.
2. Firm at time of filing is unconfirmed. Capuano's current affiliation appears to be Capuano IP PLLC (Salem, MA); he spent 2008–c. 2020 as a Duane Morris partner. I did not find a source stating which entity appeared for Albaugh here. Notably, a Docket Alarm search URL for PGR matters contains a "Duane Morris" firm filter alongside the Albaugh, LLC v. BASF SE result (https://www.docketalarm.com/search/PTAB/?fname_q_docket=Post+Grant+Review&f=party_obj.firm.name_exact_remove-Duane+Morris...), which is suggestive but not probative of the firm of record in this case.
3. No in-house or Albaugh legal-department attorney is identified in any public source. Albaugh is privately held and does not publicly list IP litigation counsel.
4. I did not find any Law360, Reuters Legal, or court-opinion coverage naming Albaugh's PGR counsel, and no PACER docket applies (this is a PTAB proceeding, not a district court case).

Two contradictions with the earlier-generated sections — flagging as required

• "Defendant representatives" section is now stale. That section states BASF's counsel "has not been publicly identified." The docket shows BASF filed a Patent Owner Mandatory Notice (Paper 4) and Power of Attorney (Paper 5) on 2026-03-25, and IP Verse identifies respondent counsel as Matias Ferrario et al. (Ferrario is a Kilpatrick Townsend & Stockton PTAB attorney who has represented BASF in numerous matters — firm attribution not verified for this case). That section should be refreshed from Papers 4–5.
• Posture has changed. The prior sections describe the case as "pre-institution as of May 29, 2026." IP Verse now reports status "Trial Instituted" with an Institution Decision Date of July 28, 2026 (https://ipverse.greyb.com/ptab-web/cases/case-details/PGR2026-00026; corroborated by the same site's Albaugh competitive-analysis page updated Sept. 18, 2026, listing status "Trial Instituted"). Given today's date (2026-10-18), the institution decision has evidently issued — well ahead of the statutory August 20, 2026 deadline. I did not locate the text of the institution decision, so I cannot report which claims/grounds were instituted.
• Technology description is inaccurate, not just "to be elaborated." The earlier overview describes the '206 patent as relating to "plant growth regulators." The petition materials describe U.S. Pat. No. 12,305,206 as "Methods for Making L-Glufosinate" — i.e., aqueous herbicidal formulations of L-glufosinate ammonium at >90% enantiomeric purity plus surfactants/solvents — and the grounds are § 102/§ 103 attacks on claims 1–6 over Long (U.S. Pat. No. 8,445,406) alone and in view of L-glufosinate synthesis references (Schulz 1990, Zeiss 1992, Grabley, Nakanishi, Minowa, Knorr), with a Dr. Suri S. Iyer declaration (Ex. 1003). The "plant growth regulator" characterization should be corrected. Sources: https://ai-lab.exparte.com/case/ptab/PGR2026-00026/doc/summary/2 and https://ai-lab.exparte.com/case/ptab/PGR2026-00026/doc/1009.

Recommended next verification steps

1. Pull Paper 1 (Petitioner POA) and the Petition's § 42.8(b)(3) notices from PTACTS for the definitive counsel table, reg. numbers, and service addresses.
2. Pull the July 28, 2026 institution decision (Paper ~7/8) — it will list counsel of record for both sides on its caption page.
3. Check for a Scheduling Order and any motion for pro hac vice admission, which would confirm any non-registered litigators appearing for Albaugh.

As of May 29, 2026, the counsel of record representing defendant BASF SE in PGR2026-00026 has not been publicly identified in the available search results or docket information.

The case is currently in its early pre-institution phase at the Patent Trial and Appeal Board (PTAB). While the petitioner, ALBAUGH, LLC, has filed a Power of Attorney identifying their counsel, there is no public record of a corresponding "Patent Owner Power of Attorney" or "Entry of Appearance" filed by BASF SE, nor any mention of their legal representation in news or docket summaries specific to this PGR proceeding.

It is typical for patent owners in PTAB proceedings to formally enter an appearance and/or file a Patent Owner Preliminary Response (POPR) after the petition is filed, which would disclose their legal counsel. Given the petition was filed on February 20, 2026, the deadline for such a response or appearance may still be pending or has passed without publicly available documentation in the search results.

Therefore, without specific docket entries or official filings from BASF SE in PGR2026-00026, the counsel of record for the defendant remains undisclosed.